Comparison of various regimens of radiomodification with cispfatin in radiation therapy for patients with oraf cavity and oropharynx cancers

Chelyabinsk Regional Cancer Center Russian Scientific Center ofRoentgenoradiology, Chelyabinsk The randomized study was undertaken to compare 3 regimens of cisplatin administration in patients with oral cavity and oropharynx cancers. Patients of group A received cisplatin at a dose of 6 mg/m2 daily, group B- 40 mg/m2 daily and group C-100 mg/m2 every 3 weeks. Beginning from the first day of cisplatin administration all patients received 68-70 Gy radiotherapy (EBRT) with conventional fractionation 2 Gy per fraction, 5 days a week. For the total radiotherapy dose of 70 Gy, the least commulative dose of cisplatin was 210 mg/m2 in group A, 280 mg/m2 in group В and 300 mg/m2 in group C. The treatment was interrupted due to toxic reactions in 18 (81.8%) patients of group A, in 17 (65.4%) patients of group В and in 5 (41.7%) patients of group C. Despite the least commulative dose of cisplatin in group A, the rate of complete tumor resorption was higher in group A (27.3%) than in groups В and С (19.2% and 16.7%, respectively).